This study presents an integrative informatics framework that effectively maps the polypharmacology of BCR-ABL inhibitors, highlighting their potential for repurposing in neurodegenerative, fibrotic, autoimmune, and metabolic diseases. The gene discussed is ABL1; the disease is Other metabolic disease.